Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson's Disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. IPXL and GlaxoSmithKline GSK today announced top-line results of the ASCEND-PD Phase III clinical study of IPX066 versus carbidopa-levodopa plus entacapone, in patients with advanced Parkinson's disease. IPX066 is an extended release capsule formulation of carbidopa-levodopa (CD-LD) under investigation for the treatment of the motor symptoms of PD.